Veloxis Pharmaceuticals A/S

VELO

DK0060048148

Pharmaceuticals

Delayed Nasdaq Copenhagen Other stock markets			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

2022	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
2021	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI

Veloxis Pharmaceuticals A/S Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Provides Earnings Guidance for the Year 2017

November 14, 2017 at 09:54 pm IST

Veloxis Pharmaceuticals A/S reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported net revenue of USD 5,924,000 compared to USD 2,239,000 in the same period of 2016. Operating loss was USD 4,174,000 compared to USD 7,290,000 in the same period of 2016. Loss before tax was USD 4,792,000 compared to USD 7,554,000 in the same period of 2016. Net loss for the period was USD 4,174,000 compared to USD 7,554,000 in the same period of 2016. Cash flow used in operating activities was USD 3,567,000 compared to USD 7,057,000 in the same period of 2016. Purchase of property, plant and equipment was USD 402,000 compared to USD 44,000 in the same period of 2016.

For the nine months, the company reported net revenue of USD 22,092,000 compared to USD 5,506,000 in the same period of 2016. Operating loss was USD 6,674,000 compared to USD 23,814,000 in the same period of 2016. Loss before tax was USD 8,116,000 compared to USD 23,961,000 in the same period of 2016. Net loss for the period was USD 8,421,000 compared to USD 23,961,000 in the same period of 2016. Cash flow used in operating activities was USD 6,386,000 compared to USD 26,595,000 in the same period of 2016. Purchase of property, plant and equipment was USD 564,000 compared to USD 125,000 in the same period of 2016.

Veloxis maintains its 2017 outlook of operating loss before the recognition of income from license agreements and before accounting for stock compensation in the range of USD 10 - 15 million.

Latest news about Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	28/22/28	CI
Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	26/21/26	CI
Veloxis Pharmaceuticals A/S Announces Board Appointments	17/20/17	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	07/20/07	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	30/20/30	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	30/20/30	CI
Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	14/20/14	CI
Transcript : Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call	25/19/25
Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	25/19/25	CI
Transcript : Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019	13/19/13
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	12/19/12	CI
Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	31/19/31	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) added to S&P Global BMI Index	23/19/23	CI
Transcript : Veloxis Pharmaceuticals A/S, Q2 2019 Earnings Call, Aug 09, 2019	09/19/09
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Second Quarter Ended June 30, 2019	09/19/09	CI
Veloxis Pharmaceuticals Revises Outlook for Full Year 2019	22/19/22	CI
Veloxis Pharmaceuticals A/S Reports Earnings Results for the First Quarter Ended March 31, 2019	08/19/08	CI
Transcript : Veloxis Pharmaceuticals A/S, Q1 2019 Earnings Call, May 07, 2019	07/19/07
Veloxis Pharmaceuticals Provides Earnings Guidance for the Full Year 2019	06/19/06	CI
Transcript : Veloxis Pharmaceuticals A/S, 2018 Earnings Call, Feb 28, 2019	28/19/28
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Full Year Ended December 31, 2018	27/19/27	CI
Veloxis Pharmaceuticals A/S Announces the Promotion of Mark Hensley to Chief Commercial Officer	03/19/03	CI
FDA Approves New Indication for Envarsus XRA (Tacrolimus Extended-ReleaseTablets)	20/18/20	CI
Transcript : Veloxis Pharmaceuticals A/S, Q3 2018 Earnings Call, Nov 15, 2018	15/18/15
Veloxis Pharmaceuticals A/S Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Maintains Earnings Guidance for the Year 2018	15/18/15	CI

Chart Veloxis Pharmaceuticals A/S

Duration

Period

More charts

Company Profile

Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâs product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâs patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
MERCK KGAA	+8.05%	72.94B
SK BIOPHARMACEUTICALS CO., LTD.	-11.95%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.87%	4.78B
YUHAN CORPORATION	+3.92%	3.9B
BETTA PHARMACEUTICALS CO., LTD.	-14.26%	2.56B
INDIVIOR PLC	+20.42%	2.42B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-23.94%	2.39B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+20.02%	2.18B
SUPERNUS PHARMACEUTICALS, INC.	+3.66%	1.65B

Specialty & Advanced Pharmaceuticals